Literature DB >> 8200261

Variations of hepatitis B virus precore/core gene sequence in acute and fulminant hepatitis B.

T T Aye1, T Uchida, S O Becker, M Hirashima, T Shikata, F Komine, M Moriyama, Y Arakawa, S Mima, M Mizokami.   

Abstract

Variations of the hepatitis B virus (HBV) precore/core sequence has been shown to play a role in the development of active liver disease in chronic hepatitis B. Whether this is also an important viral factor in the pathogenesis of acute and fulminant hepatitis B is unknown. To determine the precore/core gene sequence in patients with acute and fulminant hepatitis B, 11 patients with fulminant hepatitis B and seven patients with acute hepatitis B were studied. The sequences of precore/core gene were determined by direct sequencing of the polymerase chain reaction amplicons generated from the HBV isolated from patients' serum. For the 11 patients with fulminant hepatitis B, the precore/core regions were successfully amplified in 10 patients. Eight patients exhibited precore stop codon mutations. In addition, nine of the 10 fulminant hepatitis B patients had frequent nucleotide substitutions with corresponding changes in the predicted amino acid sequences in the mid-core and the 5' terminus region of the core gene. In contrast, precore stop codon mutants were not detected, and variations of the HBV core gene were minimal in patients with acute hepatitis B. The association of HBV precore mutants and HBV core gene variations with fulminant hepatitis B and not acute hepatitis B suggested that these variations may be important in modulating the clinical course of HBV infection.

Entities:  

Mesh:

Year:  1994        PMID: 8200261     DOI: 10.1007/bf02093794

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Variations in codons 84-101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B virus infection.

Authors:  T Ehata; M Omata; O Yokosuka; K Hosoda; M Ohto
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

2.  Characterization of the major duck hepatitis B virus core particle protein.

Authors:  J Pugh; A Zweidler; J Summers
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

3.  Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope.

Authors:  D R Milich; J L Hughes; A McLachlan; G B Thornton; A Moriarty
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

4.  An improved method for directly sequencing PCR amplified material using dimethyl sulphoxide.

Authors:  P R Winship
Journal:  Nucleic Acids Res       Date:  1989-02-11       Impact factor: 16.971

5.  Topological analysis of the hepatitis B virus core particle by cysteine-cysteine cross-linking.

Authors:  M Nassal; A Rieger; O Steinau
Journal:  J Mol Biol       Date:  1992-06-20       Impact factor: 5.469

6.  Sequence comparison of the capsid region of hepatitis E viruses isolated from Myanmar and China.

Authors:  T T Aye; T Uchida; X Ma; F Iida; T Shikata; H Zhuang; K M Win
Journal:  Microbiol Immunol       Date:  1992       Impact factor: 1.955

7.  Detection of precore/core-mutant hepatitis B virus genome in patients with acute or fulminant hepatitis without serological markers for recent HBV infection.

Authors:  T Uchida; T T Aye; S O Becker; M Hirashima; T Shikata; F Komine; M Moriyama; Y Arakawa; S Takase; S Mima
Journal:  J Hepatol       Date:  1993-07       Impact factor: 25.083

8.  Hepatitis B virus and apparent fulminant non-A, non-B hepatitis.

Authors:  T L Wright; D Mamish; C Combs; M Kim; E Donegan; L Ferrell; J Lake; J Roberts; N L Ascher
Journal:  Lancet       Date:  1992-04-18       Impact factor: 79.321

9.  The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw.

Authors:  Y Ono; H Onda; R Sasada; K Igarashi; Y Sugino; K Nishioka
Journal:  Nucleic Acids Res       Date:  1983-03-25       Impact factor: 16.971

10.  Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen.

Authors:  A Penna; F V Chisari; A Bertoletti; G Missale; P Fowler; T Giuberti; F Fiaccadori; C Ferrari
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

View more
  7 in total

1.  Precore mutant of hepatitis B virus prevails in acute and chronic infections in an area in which hepatitis B is endemic.

Authors:  C M Chu; C T Yeh; C T Chiu; I S Sheen; Y F Liaw
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

2.  Replication of naturally occurring woodchuck hepatitis virus deletion mutants in primary hepatocyte cultures and after transmission to naive woodchucks.

Authors:  M Lu; G Hilken; D Yang; T Kemper; M Roggendorf
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Molecular epidemiology of an outbreak of fulminant hepatitis B.

Authors:  N Petrosillo; G Ippolito; L Solforosi; P E Varaldo; M Clementi; A Manzin
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

4.  Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan.

Authors:  T Imamura; O Yokosuka; T Kurihara; T Kanda; K Fukai; F Imazeki; H Saisho
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

5.  A defective interference-like phenomenon of human hepatitis B virus in chronic carriers.

Authors:  T T Yuan; M H Lin; D S Chen; C Shih
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

6.  Functional characterization of naturally occurring variants of human hepatitis B virus containing the core internal deletion mutation.

Authors:  T T Yuan; M H Lin; S M Qiu; C Shih
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

7.  Complete hepatitis B virus genome analysis in HBsAg positive mothers and their infants with fulminant hepatitis B.

Authors:  Michael Friedt; Patrick Gerner; Philip Wintermeyer; Stefan Wirth
Journal:  BMC Gastroenterol       Date:  2004-06-08       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.